A twice-a-year injection, recently approved for HIV prevention in the U.S. and the European Union, helps solve the problem of adherence, Gilead argues. https://www.japantimes.co.jp/business/2025/09/22/companies/gilead-twice-a-year/?utm_medium=Social&utm_source=mastodon #business #companies #hiv #medicine #gilead #pharmaceuticals #nationalhealthcare